ISA 2022 | The prognostic role of MRD in AL amyloidosis
Andrew Staron, MD, Boston Medical Centre, Boston, MA, comments on the results of a prospective study investigating the prognostic value of measurable residual disease (MRD) in AL amyloidosis. The study showed that patients with a hematologic complete response (CR) who achieved MRD negativity had statistically significant improvements across several clinical endpoints including renal response, progression-free survival (PFS) and time to next treatment, but did not experience significant improvements in overall survival (OS) or cardiac response. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
